Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma

Table 2 Results of multivariate analysis for the selected 2241 pairs

Endpoints	Variable	HR (95% CI)	P value ^a
DFS	Gender, female vs. male	0.799 (0.681–0.937)	0.006
	Age, > 44 vs. ≤ 44y	1.191 (1.041–1.362)	0.011
	LDH; > 245 vs. ≤ 245 U/L	1.596 (1.298–1.962)	< 0.001
	T category; T3–4 vs. T1–2	1.283 (1.043–1.578)	0.018
	N category, N2–3 vs. N0–1	1.742 (1.506–2.015)	< 0.001
	Overall stage, IVA vs. III	1.867 (1.632–2.136)	< 0.001
	Treatment, IC + CCRT vs. CCRT	0.955 (0.837–1.090)	0.494
OS	Gender; female vs. male	0.700 (0.562–0.871)	0.001
	Age, > 44 vs. ≤ 44y	1.479 (1.238–1.768)	< 0.001
	LDH; > 245 vs. ≤ 245 U/L	1.734 (1.343–2.238)	< 0.001
	N category, N2–3 vs. N0–1	1.922 (1.589–2.323)	< 0.001
	Overall stage, IVA vs. III	2.140 (1.795–2.550)	< 0.001
	Treatment, IC + CCRT vs. CCRT	0.894 (0.752–1.063)	0.207
DMFS	Gender; female vs. male	0.758 (0.616–0.932)	0.009
	LDH; > 245 vs. ≤ 245 U/L	1.938 (1.519–2.473)	< 0.001
	N category, N2–3 vs. N0–1	1.959 (1.649–2.327)	< 0.001
	Overall stage, IVA vs. III	1.989 (1.678–2.357)	< 0.001
	Treatment, IC + CCRT vs. CCRT	0.926 (0.782–1.096)	0.369
LRRFS	Smoking, yes vs. no	1.263 (1.024–1.557)	0.029
	Age, > 44 vs. ≤ 44y	1.345 (1.088–1.662)	0.006
	T category, T3–4 vs. T1–2	1.494 (1.062–2.103)	0.021
	N category; N3 vs. N2	1.624 (1.297–2.033)	< 0.001
	Overall stage, IVA vs. III	1.654 (1.341–2.039)	< 0.001
	Treatment, IC + CCRT vs. CCRT	1.114 (0.906–1.369)	0.306

Abbreviations: DFS disease-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, HR hazard ratio, CI confidence interval, IC induction chemotherapy, CCRT concurrent chemoradiotherapy, LDH lactate dehydrogenase
^aP-values were calculated using an adjusted Cox proportional hazards model with backward elimination and the following variables were included: gender (female vs. male), age (> 44y vs. ≤ 44y), smoking (yes vs. no), drinking (yes vs. no), family history of cancer (yes vs. no), LDH (> 245 vs. ≤ 245 U/L), T category (T3–4 vs. T1–2), N category (N2–3 vs. N0–1), overall stage (IVA vs. III) and treatment (IC + CCRT vs. CCRT)

ISSN: 1471-2407